SCHEMBL4456057

SCHEMBL4456057

NC(Cc1c(I)ccc2ccccc12)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPI P09923 1/20 0.49
PKM P14618 1/20 0.49
PTGS1 P23219 1/20 0.49
XIAP P98170 1/20 0.49
SLC7A5 Q01650 1/20 0.49
KDM4E B2RXH2 2/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
MPO P05164 1/20 0.44
TSHR P16473 1/20 0.44
BLM P54132 1/20 0.44
PMP22 Q01453 1/20 0.44
KMT2A Q03164 1/20 0.44
HIF1A Q16665 1/20 0.44
ALDH1A1 P00352 2/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL887084 0.81 ALPI (0.55) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL12434729 0.81 ALPI (0.55) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL180266 0.81 ALPI (0.55) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL29407854 0.81 ALPI (0.55) ALPIPKMPTGS1XIAPSLC7A5
Hydrochloric Acid SCHEMBL7570495 0.81 ALPI (0.47) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL3763664 0.76 KDM4E (0.67) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL93516 0.74 CTNNB1 (0.59) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL660499 0.74 CTNNB1 (0.59) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL29397858 0.74 CTNNB1 (0.59) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL29397866 0.74 CTNNB1 (0.59) ALPIPKMPTGS1XIAPSLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250312499-A1 KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2025-10-09 US claimed
EP-2015769-A2 PHARMACEUTICAL COMPOSITIONS OF HGLP-1, EXENDIN-4 AND ANALOGS THEREOF Societe de Conseils de Recherches et d'Applications Scientifique (FR) 2009-01-21 EP disclosed
EP-1999259-A2 SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES California Institute of Technology (US) 2008-12-10 EP disclosed
WO-2007131286-A1 NANOSTRUCTURES SUITABLE FOR DELIVERY OF AGENTS APOLLO LIFE SCIENCES LIMITED (AU) 2007-11-22 WO disclosed
WO-2007120899-A2 PHARMACEUTICAL COMPOSITIONS OF HGLP-1, EXENDIN-4 AND ANALOGS THEREOF SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2007-10-25 WO disclosed
WO-2007103307-A2 SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-09-13 WO disclosed
EP-0443132-A1 Peptides having tachykinin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250312499-A1 KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF KISS1R, GNRHR, PROKR1 ALPI 3847/4885PKM 1213/4885PTGS1 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.